🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Abevmy 25 mg/mL concentrate for solution for infusion., CAPECITABINE VIATRIS 150 mg, comprimé pelliculé, IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Erbitux 5 mg/mL solution for infusion, Vectibix 20 mg/ml concentrate for solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Patients with newly diagnosed advanced peritoneal metastasis from colon and colorectal junction cancer

    phase 2 small molecule active

    1 trial
  2. Abraxane 5 mg/ml powder for dispersion for infusion., IRINOTECAN VIATRIS 20 mg/ml, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, Gemcitabine Accord 100 mg/ml koncentratas infuziniam tirpalui, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, FLUOROURACILE ACCORD 50 mg/ml, solution à diluer pour perfusion, LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV)

    The George Institute

    local advenced pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial
  3. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial
  4. Abraxane, CAAA614A12101, PACLITAXEL ALBUMIN-BOUND, OXALIPLATIN, FLUOROURACIL, AAA614, IRINOTECAN, AAA514, CALCIUM FOLINATE

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial
  5. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial
  6. Acasunlimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Genmab A/S

    Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)

    phase 2 small molecule active

    1 trial
  7. Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset

    Adaptive Biotechnologies Corp

    Chronic Tonal Tinnitus

    phase 2 other completed

    1 trial
  8. Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial
  9. Active treatment with a high dose of BGS649

    Mereo BioPharma Group plc

    Endometriosis

    phase 2 small molecule completed

    1 trial
  10. Air médical en bouteille, OXYGEN

    Pari Pharma GmbH

    Alternating Hemiplegia of Childhood

    phase 2 small molecule active

    1 trial
  11. Alisertib

    Takeda

    Acute Myelogenous Leukemia

    phase 2 small molecule completed

    1 trial
  12. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial
  13. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial
  14. Alvelestat (MPH966)

    Mereo BioPharma Group plc

    Alpha-1 Antitrypsin Deficiency (AATD)

    phase 2 small molecule completed

    1 trial
  15. Alxn1920 placebo product, ALXN1920

    Alexion Europe SAS

    Primary Mebranous Nephropathy (PMN)

    phase 2 small molecule active

    1 trial
  16. Amlitelimab, Amlitelimab matching placebo comprised of the same excipients as the Test product without the active substance

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis

    phase 2 small molecule active

    1 trial
  17. Amphotericin B

    Matinas BioPharma Holdings

    Candidiasis, Chronic Mucocutaneous

    phase 2 small molecule completed

    1 trial
  18. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial
  19. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial
  20. An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 other active

    1 trial
  21. Anlotinib plus Pemetrexed

    Henan Provincial People's Hospital

    Non-squamous Cell Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  22. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial
  23. Apatinib

    The First People's Hospital of Lianyungang

    Advanced Esophageal Squamous Carcinoma

    phase 2 small molecule active

    1 trial
  24. Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution à diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution à diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution à diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution à diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources